Dr. Bruce Turner is a medically trained oncologist with deep experience spanning genetic research, drug development and healthcare portfolio management. Prior to founding Xanadu, Dr. Turner spent five years at Hoffman-La Roche in various position of increasing responsibility in R&D and was vice president at Ionis Pharmaceuticals, Inc. working in cardiovascular/ metabolic drug development. Dr. Turner is also the interim chief financial officer and chief strategy officer for Morphimmune, a targeted oncology company.  Earlier in his career, he served as a healthcare equities portfolio manager at Bank of America Merrill Lynch and Diker Management. Dr. Turner received a M.D. and Ph.D. from the University of Pennsylvania School of Medicine and a B.A. in biology from the University of Chicago. He completed his postgraduate medical training at Yale-New Haven Hospital in Radiation Oncology and performed postdoctoral research at Yale University.